Table 6.
Other intervention by group
| Intervention | Pregnant cases (n=38), n/N (%) | Nonpregnant controls (n=94), n/N (%) | P value |
|---|---|---|---|
| Hydroxychloroquine | 34/38 (89.5) | 76/94 (80.9) | .23 |
| Azithromycin | 25/38 (65.8) | 56/94 (59.6) | .51 |
| Antiviralsa | 7/38 (18.4) | 6/94 (6.4) | .05 |
| Tocilizumab | 3/38 (7.9) | 4/94 (4.3) | .41 |
| Systemic steroidsb | 4/38 (10.5) | 15/94 (16.0) | .42 |
| Convalescent plasma | 2/38 (5.3) | 4/94 (4.3) | >.99 |
| Therapeutic anticoagulationc | 8/38 (21.1) | 20/94 (21.3) | .98 |
| Prophylactic anticoagulationc | 24/38 (63.2) | 61/94 (64.9) | .85 |
| Prone positioning | 5/38 (13.2) | 7/94 (7.4) | .30 |
DeBolt et al. Severe and critical COVID-19 in pregnant vs nonpregnant controls. Am J Obstet Gynecol 2021.
a
Antivirals included remdesivir, lopinavir-ritonavir, and oseltamivir
b
Systemic steroids included prednisone, methylprednisolone, and dexamethasone
c
Anticoagulation therapy included unfractionated heparin, low molecular weight heparin, fondaparinux, and apixaban.